Payment overview · 2025
General Payments
$94.46
2 reported records · 2 companies
Healthcare provider profile · identity verified
Jose E. Castellon Miranda
Allopathic & Osteopathic Physicians|Family Medicine · YAUCO, PR · NPI 1194848309
Verified facts
What the public records show
CMS Open Payments records show Jose E. Castellon Miranda received $94.46 in general payments during 2025 across 2 reported records.
GlaxoSmithKline, LLC. accounted for 54.3% of that reported general-payment amount.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.30 | 54.3% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $43.16 | 45.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $94.46 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 646 | 122 |
| Famotidine | Famotidine | 417 | 70 |
| Metformin Hcl | Metformin Hcl | 378 | 66 |
| Lisinopril | Lisinopril | 361 | 72 |
| Gabapentin | Gabapentin | 359 | 58 |
| Losartan Potassium | Losartan Potassium | 281 | 45 |
| Omeprazole | Omeprazole | 266 | 52 |
| Simvastatin | Simvastatin | 245 | 41 |
| Synthroid | Levothyroxine Sodium | 245 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 242 | 45 |
| Alendronate Sodium | Alendronate Sodium | 213 | 38 |
| Montelukast Sodium | Montelukast Sodium | 189 | 31 |
| Amlodipine Besylate | Amlodipine Besylate | 171 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 170 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 162 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 161 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 129 | 19 |
| Allopurinol | Allopurinol | 103 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 94 | 19 |
| Furosemide | Furosemide | 93 | 20 |
| Sulindac | Sulindac | 88 | 31 |
| Dexamethasone | Dexamethasone | 86 | 67 |
| Azithromycin | Azithromycin | 85 | 66 |
| Glipizide | Glipizide | 83 | 18 |
| Cilostazol | Cilostazol | 81 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 70 | 11 |
| Carvedilol | Carvedilol | 64 | 16 |
| Glimepiride | Glimepiride | 64 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 57 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 53 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | suppressed |
| Pentoxifylline | Pentoxifylline | 50 | suppressed |
| Latanoprost | Latanoprost | 49 | suppressed |
| Atenolol | Atenolol | 48 | suppressed |
| Finasteride | Finasteride | 48 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 13 |
| Meclizine Hcl | Meclizine Hcl | 47 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 42 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 41 | suppressed |
| Ibuprofen | Ibuprofen | 35 | 17 |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 33 | suppressed |
| Digoxin | Digoxin | 32 | suppressed |
| Calcitriol | Calcitriol | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Insulin Lispro | Insulin Lispro | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Methotrexate | Methotrexate Sodium | 27 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 13 |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Verapamil Sr | Verapamil Hcl | 25 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 19 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Sure Comfort | Syringe-Needle,insulin,0.5 Ml | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | 12 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 13 |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 19 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Lumigan | Bimatoprost | 18 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Trueplus Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 16 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 15 | 15 |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Trueplus Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Travoprost | Travoprost | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Bicillin L-A | Penicillin G Benzathine | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Levoxyl | Levothyroxine Sodium | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $94.46 · 2 records | GlaxoSmithKline, LLC. | — | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error